Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation

Vaccine

Volumn 24, Issue 47-48, 2006, Pages 6893-6904

  Li, Fusheng ^a   Malhotra, Uma ^a   Gilbert, Peter B ^a   Hawkins, Natalie R ^a   Duerr, Ann C ^a   McElrath, Juliana M ^a   Corey, Lawrence ^a   Self, Steven G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

CTL; Peptide selection; Vaccine evaluation

Indexed keywords

ALANYLPHENYLALANYLARGINYLHISTIDYLVALYLALANYLARGINYLGLUTAMYLLEUCYL HISTIDYLPROLYLGLUTAMYLTYROSYLPHENYLALANYLLYSINE; ALANYLPHENYLALANYLHISTIDYLHISTIDYLMETHIONYLALANYLARGINYLGLUTAMYLLEUCYL HISTIDYLPROLYLGLUTAMYLTYROSYLTYROSYLLYSINE; ARGINYLGLUTAMINYLGLUTAMYLISOLEUCYLLEUCYLASPARTYLLEUCYLTRYPTOPHANYLVALYL TYROSYLHISTIDYLTHREONYLGLUTAMINYLGLYCYLTYROSINE; ARGINYLPROLYLMETHIONYLTHREONYLTYROSYLLYSYLALANYLALANYLLEUCYLASPARTYL LEUCYLSERYLHISTIDYLPHENYLALANYLLEUCINE; ARGINYLPROLYLMETHIONYLTHREONYLTYROSYLLYSYLGLYCYLALANYLVALYLASPARTYL LEUCYLSERYLHISTIDYLPHENYLALANYLLEUCINE; ASPARAGINYLTYROSYLTHREONYLPROLYLGLYCYLPROLYLGLYCYLTHREONYLARGINYLTYROSYL PROLYLLEUCYLTHREONYLPHENYLALANYLGLYCINE; ASPARTYLPROLYLGLUTAMYLARGINYLGLUTAMYLVALYLLEUCYLGLUTAMYLTRYPTOPHANYL ARGINYLPHENYLALANYLASPARTYLSERYLARGINYLLEUCINE; GLUTAMYLVALYLLEUCYLGLUTAMINYLTRYPTOPHYLLYSYLPHENYLALANYLASPARTYLSERYL ARGINYLLEUCYLALANYLLEUCYLARGINYLHISTIDINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISOLEUCYLPROLYLLEUCYLARGINYLPROLYLMETHIONYLTHREONYLTYROSYL LYSYLGLYCYLALANYLLEUCYLASPARTYLLEUCYLSERINE; ISOLEUCYLTYROSYLSERYLARGINYLLYSYLARGINYLGLUTAMINYLGLUTAMYLISOLEUCYL ASPARTYLLEUCYLTRYPTOPHYLISOLEUCYLTYROSINE; ISOLEUCYLTYROSYLSERYLGLUTAMINYLLYSYLARGINYLGLUTAMINYLASPARTYLISOLEUCYL LEUCYLASPARTYLLEUCYLTRYPTOPHYLISOLEUCYLTYROSINE; LEUCYLVALYLTRYPTOPHYLLYSYLPHENYLALANYLASPARTYLSERYLSERYLLEUCYLALANYL PHENYLALANYLHISTIDYLHISTIDYLMETHIONYLALANINE; LYSYLPROLYLGLUTAMINYLVALYLPROLYLLEUCYLARGINYLPROLYLMETHIONYLTHREONYL LYSYLALANYLALANYLVALINE; NEF PROTEIN; PEPTIDE DERIVATIVE; PHENYLALANYLPROLYLVALYLARGINYLPROLYLGLUTAMINYLVALYLPROLYLLEUCYLARGINYL PROLYLMETHIONYLTHREONYLTYROSYLLYSINE; PROLYLGLYCYLISOLEUCYLARGINYLTYROSYLPROLYLLEUCYLTHREONYLPHENYLALANYL GLYCYLTRYPTOPHYLCYSTEINYLPHENYLALANYLLYSYLLEUCINE; PROLYLGLYCYLPROLYLGLYCYLISOLEUCYLARGINYLTYROSYLPROLYLLEUCYLCYSTEINYL PHENYLALANYLGLYCYLTRYPTOPHYLCYSTEINYLPHENYLALANINE; PROLYLGLYCYLPROLYLGLYCYLTHREONYLARGINYLPHENYLALANYLPROLYLLEUCYLTHREONYL PHENYLALANYLGLYCYLTRYPTOPHYLCYSTEINYLPHENYLALANINE; PROLYLMETHIONYLTHREONYLTYROSYLLYSYLALANYLALANYLVALYLASPARTYLLEUCYLSERYL HISTIDYLLEUCYLLYSINE; SERYLGLUTAMINYLARGINYLARGINYLGLUTAMINYLASPARTYLISOLEUCYLLEUCYLASPARTYL LEUCYLTRYPTOPHANYLVALYLTYROSYLHISTIDYLTHREONINE; SERYLVALYLVALYLGLYCYLTRYPTOPHYLPROLYLALANYLVALYLARGINYLGLUTAMYL ARGINYLMETHIONYLARGINYLARGINYLALANINE; THREONYLARGINYLTYROSYLPROLYLLEUCYLTHREONYLPHENYLALANYLGLYCYLTRYPTOPHYL CYSTEINYLTYROSYLLYSYLLEUCYLVALYLPROLINE; TRYPTOPHYLARGINYLPHENYLALANYLASPARTYLSERYLARGINYLLEUCYLALANYLPHENYLALANYL HISTIDYLHISTIDYLMETHIONYLALANYLARGINYLGLUTAMIC ACID; TYROSYLTHREONYLPROLYLGLYCYLPROLYLGLYCYLVALYLARGINYLTYROSYLPROLYLLEUCYL THREONYLPHENYLALANYLGLYCYLTRYPTOPHAN; UNCLASSIFIED DRUG; VALYLLEUCYLMETHIONYLTRYPTOPHYLPHENYLALANYLPHENYLALANYLASPARTYLSERYLARGINYL LEUCYLALANYLPHENYLALANYLHISTIDYLHISTIDYLISOLEUCINE; VALYLLEUCYLVALYLTRYPTOPHYLLYSYLPHENYLALANYLASPARTYLSERYLARGINYL LEUCYLALANYLPHENYLALANYLARGINYLHISTIDYLMETHIONINE; VALYLPROLYLLEUCYLARGINYLPROLYLMETHIONYLTHREONYLTYROSYLARGINYLALANYLALANYL ARGINYLASPARTYLLEUCYLSERINE; VALYLTRYPTOPHYLARGINYLPHENYLALANYLASPARTYLSERYLHISTIDYLLEUCYLALANYL PHENYLALANYLARGINYLHISTIDYLMETHIONYLALANYLARGININE;

ALGORITHM; ANTIGEN RECOGNITION; ARTICLE; BIOMETRY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DATA BASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PREVALENCE; PRIORITY JOURNAL; VIRUS STRAIN;

AIDS VACCINES; ALGORITHMS; AMINO ACID SEQUENCE; DATABASES, GENETIC; EPITOPES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33846057692     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.009     Document Type: Article

References (36)

1. Musey L., Hughes J., Schacker T., Shea T., Corey L., and McElrath M.J. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 337 18 (1997) 1267-1274
2. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 5403 (1999) 857-860
3. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 5491 (2000) 486-492
4. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
5. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
6. McMichael A.J., and Hanke T. HIV vaccines 1983-2003. Nat Med 9 7 (2003) 874-880
7. Stratov I., DeRose R., Purcell D.F., and Kent S.J. Vaccines and vaccine strategies against HIV. Curr Drug Targets 5 1 (2004) 71-88
8. Sette A., Livingston B., McKinney D., Appella E., Fikes J., Sidney J., et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29 3-4 (2001) 271-276
9. Kong W.P., Huang Y., Yang Z.Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77 23 (2003) 12764-12772
10. Casimiro D.R., Bett A.J., Fu T.M., Davies M.E., Tang A., Wilson K.A., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78 20 (2004) 11434-11438
11. Smith J.M., Amara R.R., McClure H.M., Patel M., Sharma S., Yi H., et al. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses 20 6 (2004) 654-665
12. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 296 5577 (2002) 2354-2360
13. Nickle D.C., Jensen M.A., Gottlieb G.S., Shriner D., Learn G.H., Rodrigo A.G., et al. Consensus and ancestral state HIV vaccines. Science 299 5612 (2003) 1515-1518 author reply 1515-1518
14. Novitsky V., Smith U.R., Gilbert P., McLane M.F., Chigwedere P., Williamson C., et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?. J Virol 76 11 (2002) 5435-5451
15. Altfeld M., Addo M.M., Shankarappa R., Lee P.K., Allen T.M., Yu X.G., et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 77 13 (2003) 7330-7340
16. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., and Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61 1 (2000) 94-99
17. Muller T., Spang R., and Vingron M. Estimating amino acid substitution models: a comparison of Dayhoff s estimator, the resolvent approach and a maximum likelihood method. Mol Biol Evol 19 1 (2002) 8-13
18. Henikoff S., and Henikoff J.G. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA 89 22 (1992) 10915-10919
19. Nyambi P.N., Nadas A., Mbah H.A., Burda S., Williams C., Gorny M.K., et al. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol 74 22 (2000) 10670-10680
20. Zolla-Pazner S., Gorny M.K., Nyambi P.N., VanCott T.C., and Nadas A. Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. J Virol 73 5 (1999) 4042-4051
21. Novitsky V., Cao H., Rybak N., Gilbert P., McLane M.F., Gaolekwe S., et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76 20 (2002) 10155-10168
22. Brusic V., Rudy G., and Harrison L.C. MHCPEP, a database of MHC-binding peptides: update. Nucleic Acids Res 26 1 (1998) 368-371
23. Marsh S.G.E., Parham P., and Barber L.D. The HLA facts book (2000), Academic Press pp. 61-72
24. Anthony D.D., and Lehmann P.V. T-cell epitope mapping using the ELISPOT approach. Methods 29 3 (2003) 260-269
25. Draenert R., Altfeld M., Brander C., Basgoz N., Corcoran C., Wurcel A.G., et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods 275 1-2 (2003) 19-29
26. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., and Rammensee H.G. Exact prediction of a natural T cell epitope. Eur J Immunol 21 11 (1991) 2891-2894
27. Martin W., Sbai H., and De Groot A.S. Bioinformatics tools for identifying class I-restricted epitopes. Methods 29 3 (2003) 289-298
28. Bian H., Reidhaar-Olson J.F., and Hammer J. The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 29 3 (2003) 299-309
29. Jensen M.A., Li F.S., van 't Wout A.B., Nickle D.C., Shriner D., He H.X., et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77 24 (2003) 13376-13388
30. Schacker T.W., Hughes J.P., Shea T., Coombs R.W., and Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 128 8 (1998) 613-620
31. Malhotra U., Holte S., Zhu T., Delpit E., Huntsberry C., Sette A., et al. Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. J Virol 77 4 (2003) 2663-2674
32. Cao J., McNevin J., Holte S., Fink L., Corey L., and McElrath M.J. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 77 12 (2003) 6867-6878
33. Evavold B.D., Sloan-Lancaster J., and Allen P.M. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 14 12 (1993) 602-609
34. Yusim K., Kesmir C., Gaschen B., Addo M.M., Altfeld M., Brunak S., et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76 17 (2002) 8757-8768
35. Bansal A., Gough E., Sabbaj S., Ritter D., Yusim K., Sfakianos G., et al. CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides. Aids 19 3 (2005) 241-250
36. McKinney D.M., Skvoretz R., Livingston B.D., Wilson C.C., Anders M., Chesnut R.W., et al. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol 173 3 (2004) 1941-1950